hexachlorobutadiene - Davidborowski.com

HEXACHLOROBUTADIENE 61
2. HEALTH EFFECTS
Studies in animals revealed that hexachlorobutadiene causes damage to the proximal tubules of the
kidney and, to a lesser extent, to the liver. Accordingly, people with preexisting kidney and liver
damage may have compromised organ functions and are expected to be more vulnerable to chemical
insult than people with normal kidney and liver functions. Infants are more likely to be affected
following exposure to hexachlorobutadiene than adults. Studies in animals showed that young rats
were more sensitive to the acute lethal effects of hexachlorobutadiene than adults. This greater
susceptibility in newborns can be attributed to immature organ systems.
2.8 METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects
of exposure to hexachlorobutadiene. However, because some of the treatments discussed may be
experimental and unproven, this section should not be used as a guide for treatment of exposures to
hexachlorobutadiene. When specific exposures have occurred, poison control centers and medical
toxicologists should be consulted for medical advice.
2.8.1 Reducing Peak Absorption Following Exposure
Exposure to hexachlorobutadiene can occur by inhalation of vapors, ingestion, and dermal contact.
The compound can cause kidney damage and, to a lesser extent, liver damage after ingestion or if it
comes in contact with skin.
Information regarding methods for reducing absorption following exposure to hexachlorobutadiene
was obtained primarily from the HSDB. No other sources were available. If inhalation of
hexachlorobutadiene has occurred, movement of the patient to fresh air is recommended. No specific
treatment is available; however, patients are usually monitored for respiratory distress, respiratory
tract irritation, bronchitis and pneumonia. If there has been substantial ingestion of the compound,
syrup of ipecac is administered within 30 minutes of ingestion to induce vomiting. Syrup of ipecac is
usually not given in cases of severe central nervous system depression or coma because there is risk
of pulmonary aspiration. The absorption of hexachlorobutadiene may be reduced following oral
exposure by binding the compound in the gastrointestinal tract. Activated charcoal in the form of
aqueous suspension or sorbitol slurry may be administered for this purpose. However, if syrup of
ipecac is given within 1 hour of ingestion of activated charcoal, it is not effective. Another suggested